ALGS (Aligos Therapeutics) YoY EPS Growth: 90.85% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALGS Aligos Therapeutics Inc ALGS
44 GF Score
Price $7.27
GF Value $34.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Aligos Therapeutics YoY EPS Growth?

Aligos Therapeutics ALGS -4.84% 44 YoY EPS Growth is 90.85% as of Jun. 2026. GuruFocus rates ALGS with a GF Score™ of 44/100 and a GF Value™ of $34.33 (Possible Value Trap). The stock has 6 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Aligos Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 was 90.85%.

Aligos Therapeutics's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.14.

Aligos Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Aligos Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aligos Therapeutics YoY EPS Growth Chart

Aligos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial 70.38 30.12 39.20 38.77 88.30

Aligos Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -288.89 0.98 85.40 -4.74 90.85
ALGS
44GF Score
Aligos Therapeutics Inc ALGS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aligos Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Aligos Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-2.45--20.94)/ | -20.94 |
=88.30 %

Aligos Therapeutics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.14--1.53)/ | -1.53 |
=90.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 90.85% mean?
Aligos Therapeutics (ALGS) has a YoY EPS Growth of 90.85% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Aligos Therapeutics and its competitors.
Is Aligos Therapeutics' YoY EPS Growth too high?
Aligos Therapeutics' current YoY EPS Growth is 90.85%. Overall, Aligos Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' YoY EPS Growth compare to CRVO and PVCT?
Aligos Therapeutics' YoY EPS Growth of 90.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Aligos Therapeutics and its competitors. Aligos Therapeutics's current YoY EPS Growth is 90.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $34.33, compared to a current price of $7.27 — trading 78.8% below its estimated fair value. The current YoY EPS Growth is 90.85%. Aligos Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current YoY EPS Growth is 90.85% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aligos Therapeutics (ALGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued. The current stock price of $7.27 is trading 78.8% below its estimated GF Value™ of $34.33. GuruFocus considers Aligos Therapeutics to be Possible Value Trap.

Key valuation signals for ALGS:

  • YoY EPS Growth: 90.85%
  • GF Value™: $34.33 vs. price of $7.27 (78.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges 5WK0:Germany
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score

Get the complete analysis for ALGS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.27
Price
$34.33
GF Value